SBI Life stock price target raised to INR2,250 by CLSA on strong margins

CLSA has raised its price target for SBI Life Insurance Co Ltd (NS:SBILIFE) to INR2,250 from INR2,180, maintaining an Outperform rating, primarily due to strong value of new business (VNB) margins of 27.8% in H1 FY26, which exceeded estimates driven by a favorable product mix. Despite a modest 10% APE growth in Q2 FY26 and an 80 basis point margin impact from GST input tax credit loss, management's commitment to full-year APE guidance and plans to offset margin pressures underpin CLSA's outlook, leading to a slight 2% trim in FY26 VNB estimates but largely stable FY27-28 projections.

Analysis

CLSA has increased its price target for SBI Life Insurance (SBILIFE) to INR2,250 from INR2,180, maintaining an Outperform rating, primarily driven by robust value of new business (VNB) margins. The insurer reported a VNB margin of 27.8% in H1 FY26, a 100 basis point year-over-year improvement and 80 basis points above CLSA's forecast, attributed to a strategic shift in product mix away from unit-linked insurance plans.

Despite a modest 10% annual premium equivalent (APE) growth in Q2 FY26, management reiterated its full-year guidance of 13%-14% individual APE growth, indicating confidence in future momentum. The company faces an 80 basis point negative impact on margins due to the loss of Goods and Services Tax (GST) input tax credit, which management plans to offset through internal adjustments and product mix changes without burdening distributors.

CLSA anticipates a 30 basis point margin reduction in FY26 and has trimmed its VNB estimate for the period by 2% to account for these factors. However, the firm's FY27-28 VNB estimates remain largely stable, with approximately 1% upward revisions, suggesting a positive long-term outlook for SBILIFE's profitability and operational efficiency.

Key Decisions for Investors

• Investors should consider the sustained Outperform rating and increased price target as a positive indicator for SBI Life's long-term investment potential.
• Closely monitor SBI Life's execution on its full-year APE growth guidance and its success in offsetting the GST input tax credit impact through product mix adjustments.
• Evaluate the strategic shift in product mix, particularly away from ULIPs, as a critical factor for continued VNB margin expansion and operational efficiency.